Natural History Tissue Study: Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)  

CLINICALTRIALS.GOV IDENTIFIER: NCT05237934

PHASE: Observational

STATUS: Recruiting*

Dr. Jaydira Del Rivero Discusses Natural History Tissue Study: (NENs) and (ACC)

Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from low grade neuroendocrine tumors (NETs) to high grade neuroendocrine carcinomas (NECs). 

These tumors often occur in the gastrointestinal tract, pancreas, lungs, adrenal medulla (pheochromocytomas) or adrenal cortex (adrenocortical cancer) and other areas of the body mentioned below:

• Gastroenteropancreatic neuroendocrine tumors (GEP-NET): stomach, duodenum, pancreas, colon, appendix, etc.

• Liver and gallbladder

• Adrenal tumors

• Pituitary gland

• Thyroid gland: medullary thyroid carcinoma

• Parathyroid tumors

• Pulmonary neuroendocrine tumors: typical and atypical carcinoid, small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC)

• Extrapulmonary small cell cancer

• Peripheral nervous system tumors: paraganglioma, neuroblastoma)

• Breast and genitourinary tract

Their rates are rising in the United States and worldwide. Researchers want to learn more about NENs through this natural history study.

OBJECTIVE:

To study the natural history of people with NENs and obtain samples from them to learn more about the disease. The clinical management of all NETs is not standardized, with only a few FDA-approved therapies and we would like to learn which combination therapeutic approach should be used, how long treatment should be continued, and in what subgroup of NENs a particular treatment option should be used.

ELIGIBILITY:

People aged 18 and older who have or are suspected to have NENs or ACC.

According to Dr. Del Rivero, this study will “give patients hope for new treatment options. Information from the study will be shared broadly with physicians. The goal of the study is to have a greater understanding of how NENs behave so we can develop new treatments that both improve patients’ quality of life and extend their lives.”

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

*NCI reimburses travel and lodging.

Download reimbursement information in English.

Download reimbursement information in Spanish.

CONTACTS:

Jaydira Del Rivero, MD

EMAIL: jaydira.delrivero@nih.gov